At Rarity Bioscience, innovation is not just what we do, it is who we are. Built on a groundbreaking technology platform and backed by a team with broad expertise, we are committed to make a meaningful change in precision medicine.
superRCA® technology originated in 2015, when PhD Lei Chen and Professor Ulf Landegren of the Molecular Tools group at the Department of Immunology, Genetics, and Pathology developed a new approach rooted in decades of innovation in padlock probes and rolling circle amplification.
The first clinical exploration was done together with Uppsala Academic Hospital and SciLifeLab and showed that superRCA detected common AML mutations with higher sensitivity than established methods like ddPCR and NGS. Follow-up analysis also indicated that relapse could have been identified up to three months earlier (Lei et al., Nature Communications).
In 2021, Rarity Bioscience was founded as a spin‑out from Uppsala University to bring this transformative technology to clinical and research settings.
Our first commercial assay, launched in 2025 for NPM1, has since been joined by a growing portfolio of superRCA kits.
superRCA® technology originated in 2015, when PhD Lei Chen and Professor Ulf Landegren of the Molecular Tools group at the Department of Immunology, Genetics, and Pathology developed a new approach rooted in decades of innovation in padlock probes and rolling circle amplification.
The first clinical exploration was done together with Uppsala Academic Hospital and SciLifeLab and showed that superRCA detected common AML mutations with higher sensitivity than established methods like ddPCR and NGS. Follow-up analysis also indicated that relapse could have been identified up to three months earlier (Lei et al., Nature Communications).
In 2021, Rarity Bioscience was founded as a spin‑out from Uppsala University to bring this transformative technology to clinical and research settings.
Our first commercial assay, launched in 2025 for NPM1, has since been joined by a growing portfolio of superRCA kits.
Improve patient outcome by making ultra-sensitive mutation detection available to everyone.
We push the boundaries of science with one shared mission:
we enable tomorrow’s precision medicine, today.
Improve patient outcome by making ultra-sensitive mutation detection available to everyone.
We push the boundaries of science with one shared mission:
we enable tomorrow’s precision medicine, today.
The best part is working at the intersection of cutting-edge science and real-world impact. As a product development scientist, I get to take ideas from concepts to something that could be used in a clinical setting.
What keeps me motivated is the purpose behind it. Knowing that improving detection accuracy could enable earlier diagnosis or better disease monitoring makes the work feel meaningful beyond the lab.
If our work helps shift healthcare toward earlier detection and more personalized treatment strategies, that would have a significant impact.
The best part is working at the intersection of cutting-edge science and real-world impact. As a product development scientist, I get to take ideas from concepts to something that could be used in a clinical setting.
What keeps me motivated is the purpose behind it. Knowing that improving detection accuracy could enable earlier diagnosis or better disease monitoring makes the work feel meaningful beyond the lab.
If our work helps shift healthcare toward earlier detection and more personalized treatment strategies, that would have a significant impact.
Are you eager to work with state-of-the-art biotechnology, collaborate with a forward-thinking team, and drive innovation in research and development? If so, Rarity Bioscience is the perfect place for you! At Rarity Bioscience, you will be at the forefront of advancing precision diagnostics and transforming healthcare.
Interested in joining? Discover more through our career center:
Are you eager to work with state-of-the-art biotechnology, collaborate with a forward-thinking team, and drive innovation in research and development? If so, Rarity Bioscience is the perfect place for you! At Rarity Bioscience, you will be at the forefront of advancing precision diagnostics and transforming healthcare.
Interested in joining? Discover more through our career center:
CEO
Co-Founder & CTO
Director of Operations, Quality & Regulatory
Director of Sales
Director of scientific operations
CO-Founder & Chairman of the Board
CO-Founder
& Board Member
Board Member
Board Member
Board Member
Co-Founder & Board Member
Board member
CO-Founder & Chairman of the board
Co-Founder & Board member
Board member
Board Member
BOARD MEMBER
Co-Founder & BOARD MEMBER
Board Member
Strategic Business Advisor
Scientific Advisor
Scientific Advisor
STRATEGIC BUSINESS ADVISOR
Scientific Advisor
Scientific Advisor
UPPSALA, SWEDEN, and SALT LAKE CITY (February 3, 2026) – Sweden-based Rarity Bioscience today announced that ARUP Laboratories, a leading national reference laboratory and nonprofit enterprise of the University of
With a growing customer base in North America, Rarity Bioscience has now established a subsidiary, Rarity Bioscience Inc., incorporated in Delaware, USA — a key step in strengthening our international
Rarity Bioscience has received the prestigious Disruptive Technology Award for its proprietary technology, superRCA™, which enables exceptionally sensitive detection of DNA mutations in common samples. The technology can detect a
About Rarity Bioscience
From discovery to technology
The Origins of the Technology
superRCA technology was first discovered and developed in 2015 by PhD Lei Chen and Professor Ulf Landegren in the Molecular Tools group at the Department of Immunology, Genetics, and Pathology. The method builds on decades of pioneering research into padlock probes and rolling circle amplification.
Between 2018 and 2020, the first clinical application in leukemia was explored in collaboration with Uppsala Academic Hospital and SciLifeLab. In these studies, superRCA demonstrated the ability to detect common mutations in Acute Myeloid Leukemia (AML) with markedly higher sensitivity than conventional methods such as ddPCR and NGS. Analysis of longitudinal follow‑up samples further showed that relapse could have been detected up to three months earlier (Lei et al., Nature Communications).
Rarity Bioscience was founded in 2021 as a spin‑out from Uppsala University to advance and commercialize the groundbreaking superRCA® assay technology.
Our first standardized product, launched in 2025, targeted NPM1 and has since been followed by a growing range of kits for diverse applications.
In 2025, we entered a global distribution partnership with Beckman Coulter Life Sciences, making superRCA products instantly accessible to laboratories worldwide.
In 2026, ARUP Laboratories in Salt Lake City, USA, announced the validation of one of our superRCA assays. Later that same year, we launched our first standardized product developed in close collaboration with a BioPharma partner.
Get to know Shirin Khalilizar
Development Scientist at Rarity Bioscience
What is the best part about working at Rarity Bioscience?
– The best part is working at the intersection of cutting-edge science and real-world impact. As a product development scientist, I get to take ideas from concepts to something that could actually be used in a clinical setting.
It’s also a very collaborative and agile environment, being part of a small, highly skilled team means you can move quickly, test ideas, and see the results of your work almost in real time. That makes the work both exciting and very tangible.
What drew you to this work, and what keeps you motivated?
– I was initially drawn to the scientific challenge, developing methods to detect rare mutations pushes the limits of sensitivity, specificity, and assay design, which I find really engaging from a technical perspective.
What keeps me motivated is the purpose behind it. Knowing that improving detection accuracy could enable earlier diagnosis or better disease monitoring makes the work feel meaningful beyond the lab.
For me, meaningful work is when the technical problems you solve are clearly connected to improving patient care and enabling more precise clinical decisions.
What impact do you hope your work will have in the long term?
– In the long term, I hope the products and technologies we’re developing become part of routine diagnostics, tools that clinicians can rely on for highly sensitive and accurate detection of disease.
If our work helps shift healthcare toward earlier detection and more personalized treatment strategies, that would have a significant impact.
Ultimately, I’d like to contribute to making precision medicine more accessible and actionable, so that even very small molecular signals can lead to meaningful clinical insights.
Ove Öhman
Scientific Advisor
Experience and previous assignments
Former senior research fellow at J&J and Pharmacia. Serial Entrepreneur, with several successful ventures.
LINUS BOSAEUS
CEO
Experience and previous assignments
Director of Operations (2019-2021) and VP Operations Clinical Trials (2021) at NuvoAir. Head of Development (2012-2016) and CEO (2016-2018) at Endovab. Research Engineer and FOI including risk management and long term planning. Board member at Endovab, and Muntra, a cloud based journal system for dental care.
Lei Chen
CO-FOUNDER & CTO
Experience and previous assignments
Bachelor’s Degree in biotechnology (2004-2008) at Nanjing University, China.
Master’s Degree in Applied Biotechnology (2008-2010) at Uppsala University, Sweden.
Host seminars in Liquid Biopsy course at EMBL (2018-2021).
Active collaborations with the IVD industry on the consulting base.
Hanna Kocken
Director of Operations, Quality & Regulatory
Experience and previous assignments
Thermo Fisher Scientific (2022-2015): Senior Manager Research & Development, Acting Director Regulatory Affairs, Quality and Regulatory Lead. ÅF/AFRY (2015-2011): Product Compliance Consultant, assignments for IVD, Medical Device and Life Science business. Bactiguard (2011-2005): Quality System Manager, Technical Product Manager, Project Manager. MeTaCot (2005-2003): Research Engineer.
Magnus Aronsson
SALES DIRECTOR
Experience and previous assignments
Business Product Manager (2021-2025), International Product Manager (2019-2021), International Healthcare Consultant (2016-2019) and Strategic sales (2010-2016) at Roche Diagnostics. Staff Engineer at Ortho Clinical diagnostics (2006-2010).
Marie Engvall
DIRECTOR OF SCIENTIFIC OPERATIONS
Experience and previous assignments
RnD Manager at Rarity Bioscience (2024-2025), Team manager Analysis Service at Olink Proteomics (2021-2024), Clinical Molecular Geneticist Team leader (2019-2021), Clinical Molecular Geneticist (2011-2019) at Uppsala University Hospital
Per Matsson
CO-FOUNDER & CHAIRMAN OF THE BOARD
Experience and previous assignments
Head of R&D (immunology) at Sanofi Diagnostics Pasteur Inc. VP of R&D at Pharmacia Diagnostics AB, with development and registration of diagnostic products throughout the world including Europe, US and Japan.
Ulf Landegren
CO-FOUNDER & Board member
Experience and previous assignments
Research in my lab has resulted in 10 companies, including ParaAllele, Olink Bioscience (renamed Navinci), Halo Genomics, Q-linea, Olink Proteomics and Rarity Bioscience
Alex Basu
Board member
Experience and previous assignments
Investment Manager at Navigare Ventures, a direct-investment arm of Wallenberg Investments.
Joseph Bernardo
Board member
Experience and previous assignments
Joseph Bernardo is currently Operating Partner at Linden Capital Partners, a Chicago based private equity firm specialized in Healthcare, as well as board chairman at StatLab. He has previously held several senior operational positions in life science and the diagnostic industry, including President at Next Gen Sequencing and Oncology at Thermo Fisher Scientific, SVP Lab Business at Siemens, as well as several board and advisory positions including, BioIVT, Boston Consulting Group, Chairman at SeraCare, Mobidiag, and Board Chairman at Lunaphore.
Nicolas Roelofs
STRATEGIC BUSINESS ADVISOR
Experience and previous assignments
Nick has over 40 years of leadership in life sciences tools and diagnostics, shaping strategy at companies like Agilent Technologies and Bio-Rad Laboratories. As President of Agilent’s Life Sciences Group, he led a $4 billion business and acquisitions like Halo Genomics. At Bio-Rad, he drove market growth and innovation. Known for strategic vision and operational excellence, he helps companies scale and advises private equity firms such as Summa Equity. Notably, he guided investments in Olink, leading to its sale to Thermo Fisher. His board roles include 908 Devices, The Binding Site, and Velsera.
Carl-Henrik Heldin
SCIENTIFIC ADVISOR
Experience and previous assignments
Professor Carl-Henrik Heldin is a renowned leader in cancer research with over 40 years of experience in molecular biology and oncology. As a Professor at Uppsala University and Chairman of the Nobel Foundation, he has significantly advanced our understanding of cell signaling, particularly through his work on growth factors receptors. His research has been pivotal in identifying mechanisms behind cancer cell growth and metastasis, paving the way for new therapeutic approaches.
Andrea Ballagi
Board member
Experience and previous assignments
Andrea Ballagi has extensive international experience from leading positions within the diagnostics and life science sectors. She has held several key operational roles, including Vice President of Sales and Marketing and Chief Operating Officer. During her tenure at Olink, she played a central role in transforming the company into a global market leader, a journey that culminated in its acquisition by Thermo Fisher Scientific in 2024. Andrea has also held senior positions at IDEXX Laboratories, further strengthening her global industry insights. She combines strategic expertise with a deep ability to apply science to meet market needs, making her a valuable addition to the board of directors.
Wim Van Criekinge
Board member
Experience and previous assignments
Wim Van Criekinge is a tenured professor at Ghent University and a co-founder of Novalis Biotech Incubation. As the head of the laboratory for computational genomics and bioinformatics (BIOBIX) and the core sequencing facility (NXTGNT), he has established a global collaborative reach across applied bioscience and clinical discovery. Wim’s laboratory was a pioneer in employing routine whole epigenomics sequencing for diagnostic discovery, leading to nearly 200 peer-reviewed publications. Beyond academia, he has a strong track record of translating bioinformatics and (epi)genetics into successful biotech business concepts, including the founding of startups such as Devgen and Genohm. He currently serves as the CSO of MDxHealth and holds several board positions in the biotech sector. Wim holds a Master’s degree in Chemical Engineering and a Ph.D. in Molecular Biology from Ghent University.
Provide your email to get access to this, and all our other documents!
Thank you for submitting the form!
